Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
用户OprrOZEymnvc
54分钟前
11
10
已完结
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-11-11 17:11:24 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

